Drugs / [68Ga] MDM2/MDMX Peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06443762 | Jan → May 2025 | — | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga] MDM2/MDMX Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06443762 ↗ |
| Modality | Peptide | “Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals” NCT06443762 ↗ |
| Route | Intravenous | “Patients are intravenously injected with prepared and quality-assured \[68Ga\] MDM2/MDMX Peptide” NCT06443762 ↗ |
| Target | MDM2 | “Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals” NCT06443762 ↗ |